Mesenchymal stromal cells (MSC) have shown potential efficacy in both animal and human
trials of acute respiratory distress syndrome (ARDS). Especially during the COVID-19 …

Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate.
Survivors usually have low quality of life. Current clinical management strategies are …

Background Lung diseases such as acute respiratory distress syndrome (ARDS) have a
high incidence worldwide. The current drug therapies for ARDS have supportive effects …

Severe cases of COVID-19 infection, often leading to death, have been associated with
variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal …

There is considerable interest in the potential for cell-based therapies, particularly
mesenchymal stromal cells (MSCs) and their products, as a therapy for acute respiratory …

Introduction: Mesenchymal stromal (stem) cell (MSC) therapies are emerging as a promising
therapeutic intervention in patients with Acute Respiratory Distress Syndrome (ARDS) and …

Background Acute respiratory distress syndrome (ARDS) is the devastating complication of
the new COVID-19 pandemic, directly correlated with releasing large amounts of …

The serious consequences of the global coronavirus disease 2019 (COVID-19) pandemic
have prompted a rapid global response to develop effective therapies that can lessen …

Background: In coronavirus disease 2019 (COVID-19) patients, elevated levels of
inflammatory cytokines from over stimulation of immune cells have become a concern due to …

Introduction Meta-analyses have been suggested to be the highest form of evidence
available to clinicians to guide clinical practice in critical care. The purpose of this study was …